- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Podcast: This Week in Managed Care—Insurance Coverage Gains Reverse and Other Health News
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This week, the top managed care stories included a report that insurance coverage gains are reversing; a deal to lower the cost of Praluent for Express Scripts members; findings that synthetic opioids are playing a bigger role in overdose deaths.
iTunes: http://apple.co/2eYWTss
TuneIn: http://bit.ly/2gv7iwj
Stitcher: http://bit.ly/2gCqtFg
Listen above or through one of these podcast services:
Increases in Insurance Coverage Rates From ACA Beginning to Reverse
Dr Jay Edelberg on Safety, Efficacy of Praluent and Remaining Payment Challenges
Synthetic Opioids Overtake Prescription Opioids as Driver of Overdose Deaths in 2016
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
Verma Highlights CMS Initiatives to Empower Patients and Promote Competition
Former HHS Secretary Price Identifies a Path to Moving Forward in Healthcare Reform
15th Annual World Health Care Congress
Read more about the stories in this podcast:
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Powles Highlights “Transformative” Benefit of EV Plus Pembro While Sharing Long-Term Data for EV-302
February 15th 2025The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
Read More
